Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage.

Notarnicola M, Tutino V, Calvani M, Lorusso D, Guerra V, Caruso MG.

J Gastrointest Cancer. 2012 Sep;43(3):508-11. doi: 10.1007/s12029-011-9300-2.

PMID:
21727995
2.

Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients.

Wang Y, Kuhajda FP, Li JN, Pizer ES, Han WF, Sokoll LJ, Chan DW.

Cancer Lett. 2001 Jun 10;167(1):99-104.

PMID:
11323104
3.

Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.

Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY.

Dis Colon Rectum. 2006 Jun;49(6):883-94.

PMID:
16741643
4.

Circulating levels of periostin may help identify patients with more aggressive colorectal cancer.

Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ.

Int J Oncol. 2009 Mar;34(3):821-8.

PMID:
19212687
5.

Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.

Ochiai H, Ohishi T, Osumi K, Tokuyama J, Urakami H, Seki S, Shimada A, Matsui A, Isobe Y, Murata Y, Endo T, Ishii Y, Hasegawa H, Matsumoto S, Kitagawa Y.

Surg Today. 2012 Jan;42(2):164-8. doi: 10.1007/s00595-011-0044-1. Epub 2011 Nov 11.

PMID:
22075664
6.

Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.

Mroczko B, Groblewska M, Wereszczyńska-Siemiatkowska U, Okulczyk B, Kedra B, Łaszewicz W, Dabrowski A, Szmitkowski M.

Clin Chim Acta. 2007 May 1;380(1-2):208-12. Epub 2007 Feb 27.

PMID:
17368603
7.

Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.

Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J.

Cancer Res. 2001 Mar 15;61(6):2523-32.

8.

Fatty acid synthase hyperactivation in human colorectal cancer: relationship with tumor side and sex.

Notarnicola M, Altomare DF, Calvani M, Orlando A, Bifulco M, D'Attoma B, Caruso MG.

Oncology. 2006;71(5-6):327-32. Epub 2007 Aug 8.

PMID:
17687193
9.

[Receptors of selected cytokines and angiokine bFGF in patients with colorectal cancer (a preliminary study)].

Grotowski M, Piechota W.

Pol Merkur Lekarski. 2001 Nov;11(65):398-401. Polish.

PMID:
11852807
10.
11.

Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer.

Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M.

Int J Oncol. 2012 Feb;40(2):560-6. doi: 10.3892/ijo.2011.1247. Epub 2011 Oct 31.

PMID:
22038159
12.

Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.

Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N.

J Natl Cancer Inst. 1999 May 19;91(10):869-74.

PMID:
10340907
13.

Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.

Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ.

Acta Oncol. 2010 Aug;49(6):805-11. doi: 10.3109/0284186X.2010.491086.

PMID:
20524776
14.

Preoperatively molecular staging with CM10 ProteinChip and SELDI-TOF-MS for colorectal cancer patients.

Xu WH, Chen YD, Hu Y, Yu JK, Wu XG, Jiang TJ, Zheng S, Zhang SZ.

J Zhejiang Univ Sci B. 2006 Mar;7(3):235-40.

15.

Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer.

Pellegrini P, Contasta I, Berghella AM, Gargano E, Mammarella C, Adorno D.

Cancer Immunol Immunother. 2000 Sep;49(7):388-94.

PMID:
10999465
16.

Prognostic value of plasma D-dimer levels in patients with colorectal cancer.

Kilic M, Yoldas O, Keskek M, Ertan T, Tez M, Gocmen E, Koc M.

Colorectal Dis. 2008 Mar;10(3):238-41. Epub 2007 Sep 13.

PMID:
17868411
17.

[The levels of selected cytokines in patients with colorectal cancer--a preliminary report].

Grotowski M, Piechota W.

Pol Merkur Lekarski. 2001 Oct;11(64):327-9. Polish.

PMID:
11770312
18.

Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer.

Liu ZP, Li LM, Liu XL, Zhang DX.

Onkologie. 2012;35(3):108-13. doi: 10.1159/000336816. Epub 2012 Feb 20.

PMID:
22414974
19.

Increased serum levels of transforming growth factor-alpha in patients with colorectal cancer.

Shim KS, Kim KH, Park BW, Yi SY, Choi JH, Han WS, Park EB.

Dis Colon Rectum. 1998 Feb;41(2):219-24.

PMID:
9556248
20.

Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.

Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.

Anticancer Res. 2000 Nov-Dec;20(6D):5195-8.

PMID:
11326694

Supplemental Content

Support Center